Merck updates on preladenant clinical program for treatment of Parkinson’s disease
Merck, known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease.